TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8297217

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg IV DMT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg IV DMT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg IV DMT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg IV DMT
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study: 2690660

Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 ml of 100% alcohol/kg body weight)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 4357135

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 400 mug daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Freon propellant alone (Control)
Number of subjects: 10
Study: 30799167

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention consisting of an educational program and a care program for managing neuropsychiatric symptoms (NPS).
Number of subjects: 274

Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 274
Study: 26764132

Group type: EXPERIMENTAL
Intervention: Professional dental education intervention (5 sessions)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Conventional dental instruction (1 session)
Number of subjects: 206
Study: 26294143

Group type: EXPERIMENTAL
Intervention: BPS group (Bacterial Pneumonia Score >4 points)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (antibiotics at physician's discretion)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: BPS group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 23143901

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo (Oseltamivir)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo (Zanamivir)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Both Oseltamivir and Zanamivir
Number of subjects: 260
Study: 22125922

Group type: EXPERIMENTAL
Intervention: Project ALERT (intervention group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 19111959

Group type: EXPERIMENTAL
Intervention: Modified AED
Number of subjects: 92

Group type: COMPARATOR
Intervention: Old AED
Number of subjects: 92
Study: 17727576

Group type: EXPERIMENTAL
Intervention: Behavioural modification (moderation of fluid intake or timing of taking anti-diuretic medication)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimuscarinic agents or desmopressin (a nona-peptide analogue of anti-diuretic hormone)
Number of subjects: 0
Study: 12880709

Group type: EXPERIMENTAL
Intervention: EMG assessment during 45 s trunk extension at 80% of maximal voluntary contraction torque
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: EMG spectral variables and torque
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ability to fatigue lumbar muscles during contraction
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Maximal voluntary contraction torque and initial median frequency at L5
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Back muscle training focused on increasing strength and self-efficacy
Number of subjects: 57
Study: 10867212

Group type: EXPERIMENTAL
Intervention: Heparin-induced extracorporeal LDL/fibrinogen precipitation (HELP)
Number of subjects: 141
Study: 9100583

Group type: EXPERIMENTAL
Intervention: Thyroxine dose changes
Number of subjects: 9
Study: 7691426

Group type: EXPERIMENTAL
Intervention: Aprotinin 1 million KIU (200,000 KIU bolus followed by 100,000 KIU/hr infusion for 8 hours)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 41
Study: 3465586

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30368347

Group type: EXPERIMENTAL
Intervention: Selective Pilates (SP)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Extension-based (EB) exercises
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 27358418

Group type: EXPERIMENTAL
Intervention: Immediate iron (I) group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Delayed iron (D) group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study: 25552609

Group type: EXPERIMENTAL
Intervention: Exercise once per week
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Exercise 3 days/week
Number of subjects: 45

Group type: COMPARATOR
Intervention: Education
Number of subjects: 45
Study: 22191456

Group type: EXPERIMENTAL
Intervention: Healthy Choices motivational interviewing intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study: 20144858

Group type: EXPERIMENTAL
Intervention: Long-term humidification therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study: 18564957

Group type: EXPERIMENTAL
Intervention: Directly applied mud pack treatment (heated mud, up to 43 degrees C, applied directly for 30 minutes, 15 applications)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nylon-covered mud pack treatment (same treatment as study group but with nylon cover)
Number of subjects: 60
Study: 15904531

Group type: EXPERIMENTAL
Intervention: Walking for transport
Number of subjects: 7247

Group type: EXPERIMENTAL
Intervention: Walking for exercise
Number of subjects: 7247
Study: 12884156

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9884381

Group type: EXPERIMENTAL
Intervention: Epinephrine (10 micromol/L)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zinterol (10 micromol/L)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Norepinephrine (10 micromol/L)
Number of subjects: 10
Study: 9116480

Group type: EXPERIMENTAL
Intervention: Function‐Oriented Guidance (FOG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Function Training (FT)
Number of subjects: 0
Study: 1884968

Group type: EXPERIMENTAL
Intervention: 1:10000 adrenalin injection
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 1:10000 adrenalin +1% aethoxysclerol injection
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Heater probe
Number of subjects: 83
Study: 6804110

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 21
Study: 29761722

Group type: EXPERIMENTAL
Intervention: Fatigue: Take Control (FTC)
Number of subjects: 74

Group type: COMPARATOR
Intervention: MS: Take Control (MSTC)
Number of subjects: 74
Study: 28653767

Group type: EXPERIMENTAL
Intervention: Positive mood condition
Number of subjects: 270

Group type: COMPARATOR
Intervention: Negative mood condition
Number of subjects: 270
Study: 27430294

Group type: EXPERIMENTAL
Intervention: ESA decision aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 23932092

Group type: EXPERIMENTAL
Intervention: M‐NBI after C‐WLI
Number of subjects: 353

Group type: COMPARATOR
Intervention: M‐NBI
Number of subjects: 353

Group type: COMPARATOR
Intervention: C‐WLI
Number of subjects: 353
Study: 22253296

Group type: EXPERIMENTAL
Intervention: 1,000 mg/d of elemental calcium carbonate plus 400 IU/d of vitamin D(3)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 20598973

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of autologous bone marrow mononucleated cells (BM‐MNCs) at 5 to 7 days after AMI
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of autologous bone marrow mononucleated cells (BM‐MNCs) at 3 to 4 weeks after AMI
Number of subjects: 192

Group type: COMPARATOR
Intervention: State-of-the-art medical management (Control)
Number of subjects: 192
Study: 17683456

Group type: EXPERIMENTAL
Intervention: Auditory white noise during cognitive tasks (self‐performed mini tasks and verbal tasks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No auditory white noise during cognitive tasks
Number of subjects: 0
Study: 15613506

Group type: EXPERIMENTAL
Intervention: Iron supplementation (3 mg/kg/day) in the iron supplemented (IS) group; n = 37
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo drops in the placebo (P) group; n = 36
Number of subjects: 73
Study: 12757987

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 45

Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 45
Study: 10536353

Group type: EXPERIMENTAL
Intervention: Cyto-Tek MonoPrep (MP) system
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional smear (CS) preparation
Number of subjects: 44
Study: 8660148

Group type: EXPERIMENTAL
Intervention: Presymptomatic gene carriers (GCs)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Non-gene carriers (non-GCs)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Gene carriers (GCs)
Number of subjects: 383
Study: 2008130

Group type: EXPERIMENTAL
Intervention: Terodiline (25 mg daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 7140008

Group type: EXPERIMENTAL
Intervention: Sodium intake
Number of subjects: 182
Study: 30482255

Group type: EXPERIMENTAL
Intervention: Sahaj Samadhi meditation (SSM)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 83
Study: 26359286

Group type: EXPERIMENTAL
Intervention: Unstably-housed adults living with HIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stably-housed adults living with HIV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 25526014

Group type: EXPERIMENTAL
Intervention: Fit Minded Tablet (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard Fit Minded (n=15)
Number of subjects: 30
Study: 24030535

Group type: EXPERIMENTAL
Intervention: Combination of hyaluronic acid (HA) and tamarind seed polysaccharide (TS‐polysaccharide)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Carmellose sodium
Number of subjects: 49
Study: 22939764

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation for 16 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 19954391

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate 0.1% cream
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Metronidazole 0.75% gel
Number of subjects: 64
Study: 17334090

Group type: EXPERIMENTAL
Intervention: Kakisu (persimmon vinegar) for 56 days (Group A)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Kakisu (persimmon vinegar) for 54 days (Group B)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Kakisu (persimmon vinegar)
Number of subjects: 81
Study: 10773104

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy (400 mg/day for 14 days every 3 months) followed by 500 mg/day of elemental calcium for 1 year
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo followed by 500 mg/day of elemental calcium for 1 year
Number of subjects: 121
Study: 8643695

Group type: EXPERIMENTAL
Intervention: Cladribine 0.10 mg/kg per day for 7 days as four monthly courses (total 2.8 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cladribine i.v. infusions of 0.10 mg, 0.05 mg, and 0.05 mg per kg of body weight per day for 7 consecutive days in three successive monthly courses (total 1.4 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1282619

Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg twice daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 2870001

Group type: EXPERIMENTAL
Intervention: Antral acidification (pH allowed to decrease)
Number of subjects: 19

Group type: COMPARATOR
Intervention: pH maintained at 4.5
Number of subjects: 19
Study: 30898234

Group type: EXPERIMENTAL
Intervention: PVAC Gold
Number of subjects: 70

Group type: COMPARATOR
Intervention: Thermocool
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both catheters
Number of subjects: 70
Study: 30183437

Group type: EXPERIMENTAL
Intervention: Absolute voice rest
Number of subjects: 20

Group type: COMPARATOR
Intervention: Relative voice rest
Number of subjects: 20
Study: 26087884

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (cycling for at least 15 minutes daily for 15 months)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (sedentary recreational activities)
Number of subjects: 114
Study: 24372367

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention in addition to standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 22883401

Group type: EXPERIMENTAL
Intervention: Qigong (White Ball exercises)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (waiting list with no qigong instruction)
Number of subjects: 16
Study: 20739450

Group type: EXPERIMENTAL
Intervention: Almond skin phenolic extract (884 mg of total polyphenols/dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 16
Study: 18076261

Group type: EXPERIMENTAL
Intervention: Repeated bout (RB) condition
Number of subjects: 31

Group type: COMPARATOR
Intervention: Single bout (CON) condition
Number of subjects: 31
Study: 16463656

Group type: EXPERIMENTAL
Intervention: L-carnitine (12 g/L in ST. Thomas cardioplegia)
Number of subjects: 23
Study: 11996470

Group type: EXPERIMENTAL
Intervention: Schedule A (carboplatin AUC 4 with topotecan 0.5 or 0.75 mg/m2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Schedule B (carboplatin AUC 4 with topotecan 0.5 or 0.75 mg/m2)
Number of subjects: 21
Study: 10520026

Group type: EXPERIMENTAL
Intervention: Complete remission
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Partial remission
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Resistant disease
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Favourable karyotype
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Intermediate karyotype
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Adverse karyotype
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: FAB type M3 without cytogenetic t(15;17)
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Good risk group (favourable karyotype or M3)
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Standard risk group (neither good nor poor)
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Poor risk group (adverse karyotype or resistant disease)
Number of subjects: 1711
Study: 7655177

Group type: EXPERIMENTAL
Intervention: Bone mineral density of the neck of femur
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Hip axis length
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Singh grade
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Combination of hip axis length and bone mineral density
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Combination of Singh grade, hip axis length, and bone mineral density
Number of subjects: 382
Study: 2119677

Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam once daily for 8 days (days 5-12)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (for 8 days, days 5-12)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2.5 mg glibenclamide once daily for 12 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glibenclamide plasma concentration-time curve
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mean oral clearance of tenoxicam
Number of subjects: 16
Study: 31387385

Group type: EXPERIMENTAL
Intervention: Color range indicator (CRI)‐based glucose meters (OneTouch Verio Flex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Color range indicator (CRI)‐based glucose meters (OneTouch Verio)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (GMs without a CRI)
Number of subjects: 0
Study: 28011003

Group type: EXPERIMENTAL
Intervention: Video game playing (VGP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Television viewing (TVV)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Challenging computer task (CT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sitting without screen exposure (control)
Number of subjects: 31
Study: 26034367

Group type: EXPERIMENTAL
Intervention: Modified sequential therapy (Group B): ilaprazole at 5 mg bid, amoxicillin and clavulanate potassium at 914 mg for the first five days, followed by ilaprazole at 5 mg bid, furazolidone at 100 mg bid, and levofloxacin at 500 mg qid for the next five days.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard quadruple therapy (Group A): ilaprazole + bismuth potassium citrate + amoxicillin and clavulanate potassium + levofloxacin.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 200
Study: 23868286

Group type: EXPERIMENTAL
Intervention: Pre‐intervention intravascular ultrasound (IVUS)
Number of subjects: 62
Study: 21443567

Group type: EXPERIMENTAL
Intervention: ARI+Li/Val
Number of subjects: 337

Group type: COMPARATOR
Intervention: PLB+Li/Val
Number of subjects: 337
Study: 19890021

Group type: EXPERIMENTAL
Intervention: Variant LH
Number of subjects: 3

Group type: COMPARATOR
Intervention: Wild-type LH
Number of subjects: 3
Study: 17420159

Group type: EXPERIMENTAL
Intervention: Peppermint oil (two enteric-coated capsules twice per day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 15815889

Group type: EXPERIMENTAL
Intervention: Inpatient topical treatment with dithranol and narrow band UV‐B 311 nm
Number of subjects: 74

Group type: COMPARATOR
Intervention: Biologics treatment with efalizumab
Number of subjects: 74
Study: 11964576

Group type: EXPERIMENTAL
Intervention: High-volume preparation of botulinum toxin-A (60 units)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low-volume preparation of botulinum toxin-A (60 units)
Number of subjects: 13
Study: 9654560

Group type: EXPERIMENTAL
Intervention: Isolated tears of lateral complete discoid meniscus, lateral incomplete discoid, or lateral semilunar meniscus
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Isolated tears of medial semilunar meniscus without obvious trauma
Number of subjects: 385
Study: 8749612

Group type: EXPERIMENTAL
Intervention: Physostigmine administered by steady-state, continuous intravenous infusion
Number of subjects: 9
Study: 2677915

Group type: EXPERIMENTAL
Intervention: Conservative functional treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Operative functional treatment
Number of subjects: 44
Study: 421639

Group type: EXPERIMENTAL
Intervention: Cryodestruction
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Closed operative hemorrhoidectomy
Number of subjects: 26
Study: 29699717

Group type: EXPERIMENTAL
Intervention: Telephone referral from Primary Health Care to Internal Medicine Consult
Number of subjects: 154

Group type: COMPARATOR
Intervention: Traditional referral from Primary Health Care to Internal Medicine Consult
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: General Practitioners in the intervention group
Number of subjects: 154

Group type: COMPARATOR
Intervention: General Practitioners in the control group
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: General Practitioners in the test group
Number of subjects: 154
Study: 28701637

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealants (Fuji Triage)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Resin-based sealants (Clinpro)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study: 25742735

Group type: EXPERIMENTAL
Intervention: Upper-body resistance exercise (ULB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower-body resistance exercise (LB)
Number of subjects: 0
Study: 23893083

Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 152
Study: 21537293

Group type: EXPERIMENTAL
Intervention: Multilayer compression bandaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antimicrobial dressings
Number of subjects: 0
Study: 19491016

Group type: EXPERIMENTAL
Intervention: (99m)Tc-NC100692, intravenous injection of 150 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (99m)Tc-NC100692
Number of subjects: 0
Study: 16982293

Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg intravenously every 8 hours
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg intravenously every 8 hours
Number of subjects: 1076
Study: 15579755

Group type: EXPERIMENTAL
Intervention: Androstenedione (100 mg)
Number of subjects: 10
Study: 11138835

Group type: EXPERIMENTAL
Intervention: Thermal cautery after surgical incision and drainage
Number of subjects: 100

Group type: COMPARATOR
Intervention: No thermal cautery after surgical incision and drainage
Number of subjects: 100
Study: 9296414

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 14

Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 14
Study: 8361987

Group type: EXPERIMENTAL
Intervention: 80 mg regular aspirin daily (14 pills)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 325 mg regular aspirin daily (14 pills)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 325 mg enteric-coated aspirin daily (14 pills)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 80 mg regular aspirin every other day (7 pills)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 80 mg daily aspirin
Number of subjects: 52
Study: 3791663

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg p.o. at 2200 and 2400 h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29388085

Group type: EXPERIMENTAL
Intervention: Intra-articular combined with intraosseous injection of PRP (administered twice, 2 weeks apart)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intra-articular injection of PRP (every 14 days)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intra-articular HA (five injections every 7 days)
Number of subjects: 86
Study: 26928796

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control (Intravenous saline infusion)
Number of subjects: 111